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WT1 encodes a transcription factor involved in kidney
development and tumorigenesis. Using representational
difference analysis, we identified a new set of WT1 tar-
gets, including a homologue of the Drosophila receptor
tyrosine kinase regulator, sprouty. Sprouty1 was up-reg-
ulated in cell lines expressing wild-type but not mutant
WT1. WT1 bound to the endogenous sprouty1 promoter
in vivo and directly regulated sprouty1 through an early
growth response gene-1 binding site. Expression of
Sprouty1 and WT1 overlapped in the developing meta-
nephric mesenchyme, and Sprouty1, like WT1, plays a
key role in the early steps of glomerulus formation. Dis-
ruption of Sprouty1 expression in embryonic kidney ex-
plants by antisense oligonucleotides reduced condensa-
tion of the metanephric mesenchyme, leading to a
decreased number of glomeruli. In addition, sprouty1
was expressed in the ureteric tree and antisense-treated
ureteric trees had cystic lumens. Therefore, sprouty1
represents a physiologically relevant target gene of WT1
during kidney development.
The development of the mammalian metanephric kidney is a
model for the study of cellular and molecular mechanisms of
organogenesis (1). Wilms tumor, a pediatric kidney malig-
nancy, is characterized by a triphasic histopathology (blast-
emal, stromal, epithelial) signifying an abnormal differentia-
tion program. In accordance with this notion, the Wilms Tumor
suppressor gene 1 (WT1), inactivated in a subset of Wilms
tumors, plays an essential role in normal development of the
kidney and the genitourinary system (2–4). Targeted disrup-
tion of WT1 in mice leads to a complete agenesis of the kidneys
and gonads (5). The specific temporal and spatial pattern of
WT1 expression suggests multiple roles for WT1 during
nephrogenesis. In particular, WT1 expression peaks during the
mesenchymal-to-epithelial transition (MET),1 suggesting an
instructive role in the formation of the renal glomerulus. In the
mature kidney, WT1 expression becomes restricted to the podo-
cytes, perhaps being involved in maintaining a differentiated
phenotype.
The WT1 gene encodes a C2-H2 zinc finger transcription
factor that binds to both GC-rich and TC repeat elements.
Alternative splicing at two sites yields four major isoforms,
each containing or lacking 17 amino acids between the trans-
activation domain and the zinc finger region and/or a 3-amino
acid insertion (KTS) between the third and fourth zinc fingers.
The KTS insertion disrupts the spacing between the zinc fin-
gers, altering DNA binding (2, 4). The A isoform lacks both
these motifs and binds strongly to DNA. The C isoform contains
the KTS insertion, displays a weaker DNA binding to alterna-
tive sequences, associates with splicing factors, and therefore,
may be involved in RNA processing. WT1 binding sites were
identified in multiple promoters that respond to WT1 in tran-
sient transfection assays (2, 6, 7); however, most are not regu-
lated by WT1 in vivo (8). Thus, identification of bona fide target
genes would provide insight into WT1 function in development
and tumorigenesis.
We previously showed that NIH3T3 cells engineered to ex-
press the WT1A isoform were growth-inhibited and displayed
partial epithelial differentiation (9). These morphological
changes correlated with significant alterations in gene expres-
sion consistent with a role for WT1 in the MET. Here, we
applied cDNA representational difference analysis (RDA (10))
to NIH3T3 cells versus WT1-expressing NIH3T3 cells and iden-
tified sprouty1 (spry1), a mammalian homologue of Drosophila
sprouty, as a gene up-regulated in response to WT1. Drosophila
sprouty was first identified as an antagonist of the branching
morphogenesis of the tracheal system and was genetically
shown to inhibit receptor tyrosine kinase signaling (11, 12). To
date, four vertebrate spry genes have been identified (13–17).
The proteins they encode share a conserved, cysteine-rich C-
terminal domain and a more divergent N-terminal domain. On
a molecular level, these proteins were shown to down-regulate
signaling by many receptor tyrosine kinases, with the notable
exception of the epidermal growth factor receptor, where
sprouty appears to increase the action of the protein (18–23). In
NIH3T3 cells Spry1 and Spry2 antagonized signaling through
multiple receptor tyrosine kinases by specific inhibition of the
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Ras/mitogen-activated protein kinase pathway but not the
phosphatidylinositol 3-kinase pathway (23); in this system sig-
nal blockade occurred at the level of Ras activation, whereas
others reported that Sprouty blocks the activation of Raf (20,
24). Precise spatial and temporal control of the Ras/Raf/mito-
gen-activated protein kinase cascade, a major pathway for
growth factors to mediate cell proliferation or differentiation, is
required for normal development. Accordingly, the Spry pro-
teins, which regulate this pathway, were implicated in branch-
ing morphogenesis of the lung, angiogenesis, and limb bud
outgrowth (14, 25, 26).
In this study, we demonstrated transcriptional regulation of
spry1 by a organ-specific transcription factor, WT1. spry1 ex-
pression was up-regulated by WT1 in several cell lines, and
WT1 directly bound and activated the spry1 promoter. In ad-
dition spry1 was dynamically expressed in the embryonic kid-
ney in a pattern partially overlapping with wt1. Disruption of
spry1 expression in kidney explants altered normal glomeruli
formation and ureteric tree morphology. Taken together, these
results demonstrate that spry1 is a WT1 target gene that may
mediate some of the regulatory effects of WT1 during kidney
organogenesis.
MATERIALS AND METHODS
Cell Culture, Transfection, and Infection—NIH3T3, maintained in
Dulbecco’s modified Eagle’s medium with 10% calf serum, were tran-
siently transfected by LipofectAMINE Plus (Invitrogen) using 0.1 g of
the various mouse spry1 luciferase reporters, 0.005 g of a thymidine
kinase Renilla reporter as internal control, and 1 g of an empty vector
(Rous sarcoma virus) or WT1 expression vectors (Rous sarcoma virus-
WT1A and WT1C (27)). Cells were harvested 48 h later and assayed for
luciferase activity using a Dual reporter assay (Promega) and for pro-
tein expression by immunoblotting. Tet-Off Saos-2 osteosarcoma cells
(a gift of Dr. D. Haber, Massachusetts General Hospital) were trans-
fected with a pTRE vector (Clontech) expressing wild-type WT1A,
WT1A112, or WT1A129 followed by selection in 0.2 g/ml puromycin.
Retroviral infection (28) and the WT1A-expressing NIH3T3 (9) were
described. mIMCD-3 (29) were maintained in Dulbecco’s modified Ea-
gle’s medium/Ham’s F-12 medium with 10% fetal calf serum.
RDA—Double-stranded cDNAs were synthesized with 5 g of
poly(A) RNA from NIH3T3 and WR16 cells, and RDA was performed
(10). To identify genes activated by WT1, three rounds of RDA subtract-
ing the 3T3 representation from the WR16 representation were per-
formed (WR16–3T3). To identify repressed genes, the reciprocal sub-
tractions were done in parallel (3T3-WR16). The differential products
were subcloned into pBluescript SK (Stratagene). To confirm that the
cDNA fragments were present in different amounts, each was 32P-
labeled and used as a probe to hybridize blots of NIH3T3 or WR16
representations. This step eliminated false positives (30%) before
sequencing.
Cloning of the spry1 cDNA—The nucleotide (nt) positions for murine
spry1 (mspry1) are listed under AF176903. From RDA, a cDNA corre-
sponding to nt 1079–1693 of mspry1 was isolated and used to identify
an EST (GenBankTM AA591484, clone ID 907842) containing nt 962–
2489 of mspry1. The 5 end of mspry1 was obtained by rapid amplifi-
cation of cDNA ends PCR (Marathon cDNA amplification kit, Clontech).
Briefly, 1 g of poly(A) RNA from podocytes was reverse-transcribed
using a mspry1 primer (nt 1016–1040). After 2nd strand synthesis and
ligation to the anchor oligonucleotide, PCR was performed using a
primer corresponding to the anchor and a mspry1 primer (nt 988–
1007). The resulting products were subcloned and sequenced. One rapid
amplification of cDNA ends product (nt 402–1007 of mspry1) was li-
gated to the above EST clone at a common StuI site. The mspry1 coding
sequence (nt 481–1469) was amplified by PCR from the full-length
cDNA and cloned in-frame with the sequence of the FLAG tag in a
modified pcDNA 3–1 () vector (30).
spry1 Genomic Cloning and Reporter Plasmids—A bacterial artificial
chromosome library was screened (Incyte Genomics, St. Louis, MO)
using primers from the mspry1 cDNA (nt 1171–1191 and 1405–1422)
and confirmed by Southern blot with a probe derived from the 5 end of
the mspry1 cDNA. A 9-kb EcoRI fragment encompassing the mspry1-
coding exon and 5 and 3 sequences was subcloned into pBluescript
SK and sequenced (MWG Biotech Inc). The start site of transcription
was mapped by primer extension. A 1.1-kb SacI fragment containing
the proximal promoter was ligated into pGL2basic (Promega). A series
of 5 truncations were created by PCR using forward primers located at
614 (5-GGTACCGGAAGAACCTTGGGC-3), 354 (5-GGTACCGG-
TGGTTTGTTATTG-3), and 137 (5-GGTACCTGCTCCGGGTTTTT-
G-3) and reverse primer located at 20 (5-AGATCTGAGCTCTGGC-
TGCGG-3) and sub-cloned with KpnI/BglII into pGL2basic. Mutations
of MIN1 (CCGGGGGCG to CCTTTTTCG-87), MIN2A (GCGTGGAG-
GTGGAGGTG to GCTTTGAGGTGTAGGTA), and MIN2B (GCGC-
GACG to GCTTTTACG) binding sites within the SPRY137-luc reporter
were created by site-directed mutagenesis (QuikChange, Stratagene).
Electrophoretic Mobility Shift Assay—Double-stranded oligonucleo-
tide probes encompassing eight putative WT1 binding sites within the
mspry1 promoter were end-labeled with [-32P]dCTP and Klenow. The
oligonucleotide probes were: Min1, 5-GACACATGATATCACCGGGG-
GCGGGTCCCG-3; MutMin1, 5-GACACATGATATCACCTTTTTCGG-
GTCCCG-3; Min2, 5-GTCCCGGCGTGGAGGTGGAGGTGGCGGCG-
ACGCT-3; Min3, 5-GCTGCGGAGCCCGCGCGCGAGTGCTCAGCAC-
GCA-3; Min4, 5-GCAGGGGTTTGCGGCGGCCCCGCAGCCAGAGC-
TC-3; Min5, 5-TCATTTAAAATGCATTGGTGTTTTGGACAAAA-3;
Min6, 5-CATTTTTTTTTTCCGTTGTTGGTGGTGGTTTGTTAT-3;
Min7, 5-CCCTGGAACGCCCGCCCCTCCCCAGTTGCGCTCGCAGG-3.
In vitro coupled transcription/translations (Promega) were per-
formed with pSP64-WT1A, pSP64-WT1C, and pSP64 control vector. 8
l of lysate were preincubated for 15 min at room temperature along
with 1 g of poly(dI-dC), 5 g of bovine serum albumin, and binding
buffer (20 mM HEPES, pH 7.5, 70 mM KCl, 5 mM MgCl2, 0.1% Nonidet
P-40, 12% glycerol, 0.5 mM dithiothreitol, 100 M ZnCl2) in a volume of
20 l followed by the addition of radiolabeled probe (50,000 cpm) for
another 15 min. Protein-DNA complexes were resolved on a 5% non-
denaturing polyacrylamide gel in 0.5 Tris-buffered EDTA at 300 V for
1.5 h. For competition experiments, 0.4 g of WT1 antibody (C-19,
Santa Cruz) or rabbit IgG (Zymed Laboratories Inc.) or a 1000 excess
of cold MIN1, MutMin1, or mut NF-B (GGCATAGGTCC) oligonucleo-
tides were added during preincubation.
Chromatin Immunoprecipitation—Proteins were cross-linked to
DNA by adding formaldehyde directly to the cell media to a concentra-
tion of 1% for 10 min at 37 °C. Cross-linking was stopped by the
addition of glycine to 0.125 M for 5 min at room temperature. Cells were
washed in phosphate-buffered saline and lysed in 1% Nonidet P-40
buffer (150 mM NaCl, 50 mM Tris, pH8, 1% Nonidet P-40, 5 mM EDTA,
protease inhibitors) for 30 min at 4 °C. The lysate was sonicated and
centrifuged, and the supernatant was diluted 10-fold in 0.1% Nonidet
P-40 buffer and precleared with protein G-Sepharose in the presence of
20 g of salmon sperm DNA and 1 mg/ml bovine serum albumin for 30
min at 4 °C. The supernatant was collected by centrifugation, 1% was
saved for total input control, and the remainder was incubated over-
night at 4 °C with or without 2 g of WT1 antibody (F6, Santa Cruz).
Immune complexes were collected with protein G-Sepharose for 1 h at
4 °C and washed in the following buffers: A (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris, pH 8, 150 mM NaCl); B (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris, pH 8, 500 mM NaCl); C (0.2 M
LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM
Tris-HCl, pH 8) and twice with Tris-EDTA, pH 8. Immune complexes
were eluted with 1% SDS, 0.1 M NaHCO3 followed by gentle centrifu-
gation. Cross-linking was reversed with NaCl (0.2 M) at 65 °C for 4 h,
and DNA was recovered by phenol/chloroform extraction and ethanol
precipitation. PCR with spry1-specific primers 20 and 137 was used
to detect spry1 promoter sequences. In a parallel experiment protein
G-Sepharose was boiled in 1 Laemmli buffer after the washes and
processed for WT1 immunoblotting.
RNA Analysis by RT-PCR and Northern Blot—Total RNA (TRIzol,
Invitrogen) or poly(A) RNA (Oligotex mRNA kit, Qiagen) were frac-
tionated on a formaldehyde-agarose gel and transferred to Hybond-N
membrane (Amersham Biosciences). The mouse Multiple Tissues
Northern blot was from Clontech. cDNA probes 32P-labeled by random
priming (23) included mspry1 (nt 1345–1652), human SPRY1 (nt 308–
1337, XM_036349), WT1 (9), rat, and human Actin. To detect mspry1 by
end-point RT-PCR, RT was performed with Superscript II reverse tran-
scriptase (Invitrogen) using 1 g of DNase-treated total RNAs and a
mspry1 reverse primer (nt 1993–2012). Next, 1⁄10 of the RT was ampli-
fied with Platinium Taq polymerase (Invitrogen) using a mspry1 for-
ward (nt 1350–1370) and reverse (nt 1633–1653) primer. RT-PCR for
WT1 was performed similarly with a forward (nt 1446–1464, Gen-
BankTM M55512) and reverse (nt 1807–1827) primer. For real time
RT-PCR (31), RT was performed with a human spry1 reverse primer
(5-GATGCCCTTGACTAAGCACATG-3). Diluted (5 l) RT products
were amplified using a PRISM® 7700 System (Applied Biosystems) in
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a volume of 25 l containing 3 mM MgCl2, PCR buffer (including SYBR
green and Rox reference dye), 200 M dNTP, 5 pmol of each primer
(reverse, as for RT; forward, 5-CCGGCAGTGCCTTTGC-3) and 0.1
unit of AmpliTaq Gold DNA polymerase (PerkinElmer Life Sciences).
Immunoblotting—A rabbit polyclonal serum was generated against a
peptide corresponding to amino acids 81–93 of mSpry1 (NP_036026)
and affinity-purified (Covance, Denver, PA). The glyceraldehyde-3-
phosphate dehydrogenase antibody (MAB374) was purchased from
Chemicon, and the WT1 antibody (C19) used in Western blot was from
Santa Cruz. Total cell lysates were analyzed by SDS-PAGE and immu-
noblotted as described (23).
Kidney Explant in Situ Hybridization (ISH) and Immunostaining,
Whole-embryo ISH—Metanephric rudiments were dissected from E11.5
embryos into minimum Eagle’s medium (Invitrogen) with 10% fetal
bovine serum, 20 mM glutamine and penicillin/streptomycin and grown
for 1–4 days on 1-m polycarbonate TranswellTM filters (Costar) at 5%
CO2, 37 °C. After fixation (4% paraformaldehyde in phosphate-buffered
saline overnight), all ISH were performed as described with hybridiza-
tions and washes carried out at 65 °C (32). Probes corresponding to nt
1345–1652 of mspry1 and nt 529–799 of mspry2 (AF176905) were
synthesized as described (33) but fragmented by alkaline hydrolysis.
Whole-embryo ISH was performed as described (34). Antibodies for
immunofluorescence included rabbit anti-Spry1 (1/500), mouse anti-
WT1 (H2, DAKO, 1/100), Cy5-conjugated goat anti-rabbit IgG, and
Biodipy-conjugated anti-mouse IgG.
Morpholino Oligonucleotide Assays—E12 fetal kidney pairs were
dissected and grown as described (35). Morpholino oligonucleotides
antisense to spry1 (ASSpry1, GGAGTGATCTCCAGTTCCAGCAGTC)
and control oligonucleotides (Ct, invert of the antisense CTGACGAC-
CTTGACCTCTAGTGAGG or random CCTCTTACCTCAGTTACAATT-
TATA) were purchased from Gene Tools (Philomath, OR) and added to
the medium (20 M) daily. Because of developmental variability within
litters, right and left kidneys from the same embryo were compared
with each other in the following ways: (i) medium versus medium plus
Ct morpholino oligonucleotides (morpholinos); (ii) medium plus Ct mor-
pholinos versus medium plus Spry1 morpholinos; (iii) medium versus
medium plus Spry1 morpholinos. After 3–5 days, the explants were
fixed (4% paraformaldehyde), the glomeruli were labeled with peanut
agglutinin (Vector Lab (36)) and counted blindly. For immunofluores-
cence, explants were fixed (4 h in 4% paraformaldehyde) and per-
meabilized overnight at 4 °C (phosphate-buffered saline, 0.05% gelatin,
0.075% saponin). Nonspecific fluorescence was blocked by ammonium
chloride (0.1 M, 2 h). The following antibodies were used: Pax2 (1:500,
PRB-276P, Covance), WT1 (1:500, sc-180, Santa Cruz), synaptopodin
(1:300, from Dr. P. Mundel, Albert Einstein), and Alexa 488-conjugated
goat-anti-rabbit IgG (1:500, Molecular Probes). Kidneys mounted on
glass slides (Vectashield, Molecular Probes) were examined using a
Leica TCS-SP (UV) confocal microscope.
RESULTS
Activation of spry1 Expression by Constitutive or Induced
WT1 Expression—To identify WT1 target genes, we applied
RDA to mRNAs extracted from parental NIH3T3 cells and
WT1A-overexpressing NIH3T3 cells (WR16 (9)). cDNAs corre-
sponding to 34 different genes were identified, and Northern
blot and RT-PCR analysis confirmed that 11 of these genes
were differentially expressed2 and not previously identified as
WT1 targets. Notable among these genes was a murine homo-
logue of Drosophila spry (11). Drosophila spry, an antagonist of
tracheal branching morphogenesis, was genetically shown to
inhibit Ras signaling (11, 12). Given the importance of branch-
ing morphogenesis in kidney development (37) and that WT1
inhibited growth of Ras-transformed cells (38), we next deter-
mined whether spry1 was a transcriptional target of WT1.
RT-PCR analysis (Fig. 1A) showed that spry1 expression was
low in NIH3T3 cells and increased in WT1-expressing cell lines
(WR16, WR35, WR14).
Because constitutive expression of WT1 may have induced
secondary changes in the NIH3T3 cells, we confirmed spry1
expression in systems with inducible expression of WT1.
NIH3T3 cells were infected at similar efficiencies with a bicis-
tronic virus harboring both WT1A and green fluorescent protein
or a control green fluorescent protein virus. As previously shown
(Fig. 1A, lane 1), basal spry1 expression was low in NIH3T3 cells
and was unaffected by infection with a control retrovirus (Fig.
1B, lane 1). In contrast, infection with retrovirus encoding WT1
markedly increased spry1 expression. The up-regulation
occurred in parallel with the accumulation of WT1 and was
observed as early as 24 h after infection (Fig. 1B, lanes 2–4).
Saos-2 cells with tetracycline-induced expression of WT1
undergo growth arrest and apoptosis (Ref. 8 and data not
shown). After WT1 expression, a 2.4-kb spry1 transcript was
readily induced in these cells (Fig. 1C). spry1 levels increased
about 10-fold (Fig. 1D) as determined by quantitative real time
PCR. Inducible expression of two tumor-associated WT1 mis-
sense mutants (F112Y and P129L) that yield proteins defective
for transcriptional activation (27) failed to up-regulate spry1
(Fig. 1D). Thus, in three different systems, endogenous spry1
expression was activated by WT1.
WT1 Directly Activates the spry1 Promoter—To determine
whether WT1 directly activates spry1 expression, regulatory
sequences for this gene were cloned and sequenced (accession
number AY260058), and the start site of transcription was
mapped by primer extension (data not shown). Within the
proximal promoter region (1.1 kb), 8 GC-rich sites were iden-
tified (Fig. 2A), matching to varying degrees previously char-
acterized WT1 binding sites: WRE (39), WTE (40), EGR1, and
synthetic sites (6). This 1.1-kb segment was linked to a lucif-
erase reporter and co-expressed in NIH3T3 cells with WT1A.
WT1A activated the reporter by a factor of 8 (Fig. 2B), consist-
ent with the magnitude of induction observed in vivo (Fig. 1D).
In contrast, activation-defective WT1A mutant proteins
(F112Y, P129L, and F154S (27)) failed to significantly activate2 I. Gross, B. Bassit, and J. D. Licht, manuscript in preparation.
FIG. 1. Confirmation of spry1 as a WT1 target gene. A, RT-PCR
showing up-regulation of spry1 expression in NIH3T3 cell lines consti-
tutively expressing WT1. Actin primers were used as internal control.
B, RT-PCR demonstrating up-regulation of spry1 expression upon ret-
rovirus-mediated WT1 expression. NIH3T3 cells were infected with
control (Ct) or WT1-encoding retrovirus (WT1) and harvested 24, 48, or
72 h later. C, Northern blot (5 g of poly(A) RNA/lane) showing
induction of spry1 expression after induction of WT1 expression in
Tet-off osteosarcoma Saos-2 cells. Actin probe was used as a loading
control. D, quantification by real time PCR of changes in spry1 expres-
sion (Expr.) 24 h after induction of wild type (wt) or mutant forms
(F112Y, P129L) of WT1 in Tet-off Saos-2 cells.
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the spry1 promoter (Fig. 2B), although these proteins bound
DNA (data not shown).
To map the WT1-responsive site, a series of truncated pro-
moter constructs (Fig. 2A) was co-transfected into NIH3T3 cells
with WT1. The shortest promoter fragment, SPRY137, con-
tained four potential binding sites and was still activated by
WT1 (Fig. 2C). The WT1C isoform (KTS) was about 50% as
active as the WT1A (KTS) isoform.
Duplex oligonucleotide probes (MIN 1–4) spanning the GC-
rich SPRY137 minimal promoter and encompassing the 4 pu-
FIG. 2. WT1 directly activates the spry1 promoter. A, diagram of spry1 proximal promoter, indicating the location of putative WT1 binding
sites. Top arrows mark the position of PCR primers for chromatin immunoprecipitation analysis. B, the full-length spry1 reporter was transiently
co-transfected into NIH3T3 cells with either a control vector (Rous sarcoma virus) or one for wild type or the indicated mutant form of WT1 (F112Y,
P129L, F154S) and a Renilla internal control vector. Activity was measured by a dual luciferase assay. The assay was performed in triplicate
(S.D.). C, a series of truncations of the spry1 promoter was tested for transactivation by WT1A and C isoforms.
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tative WT1 binding sites and 3 additional probes (MIN 5–7)
encompassing the four upstream sites were incubated with in
vitro transcribed/translated WT1A and WT1C and subjected to
a gel mobility shift assay. A strong, specific DNA-protein com-
plex was only formed between WT1A and the MIN1 probe,
corresponding to the 5 EGR1-like site within the 137-bp pro-
moter fragment (Fig. 3A, left, lane 2). On a long exposure, a
weak complex was observed with the MIN2 probe (Fig. 3A, left,
lane 5). WT1C did not bind to any of the DNA probes. Unpro-
grammed and programmed lysates formed a nonspecific com-
plex with the MIN6 probe (Fig. 3A, right, lanes 10–12). The
MIN1WT1A complex was blocked by a WT1 antibody but not a
control antibody (Fig. 3B, lanes 2 and 4). A mutant form of the
EGR1 site with all 5 critical G residues mutated to T failed to
bind to WT1A (Fig. 3C, lanes 5 and 6). Unlabeled MIN1 probe
could compete with itself for WT1A binding (Fig. 3C, lane 8),
whereas the mutant probe and an unrelated NF-B probe could
not (Fig. 3C, lanes 9 and 10). Therefore, WT1A binds directly to
a single EGR1 site within the minimal SPRY137 promoter.
Finally, to show that WT1A bound to the spry1 promoter in
vivo, a chromatin immunoprecipitation was performed using
NIH3T3 cells that express WT1A under tetracycline control
(28). Withdrawal of tetracycline induced the expression of
WT1A (Fig. 3D, lanes 5 versus 6). Only in the presence of WT1A
was the spry1 promoter precipitated by a WT1 antibody (Fig.
3D, lanes 1 versus 2) along with the WT1 protein.
Mutation of the MIN1 site in the context of the SPRY137
luciferase reporter reduced WT1-mediated transactivation by
50% (Fig. 3E). Two different mutations of MIN2, which weakly
bound WT1A in vitro, had no effect on WT1 transactivation
either alone or in combination with the MIN1 mutation (Fig.
3E). Taken together the data indicate that WT1 activates tran-
scription through direct binding to an EGR1 site within the
spry1 promoter. The residual transactivation in the presence of
a mutated MIN1 site might be due to the adjacent CAAT box
sequence, which we previously showed to promote WT1 trans-
FIG. 3. WT1 directly binds to a minimal region of the spry1 promoter. A, panels 1 and 2, oligonucleotide probes corresponding to all
putative WT1 binding sites within the spry1 promoter were incubated with rabbit reticulocyte lysate (O), in vitro expressed WT1A (A) or WT1C
(C). B, WT1 antibody (lanes 2 and 3) or rabbit IgG (lanes 4 and 5) were added for supershift analysis of MIN1/WT1A complex. C, competition
analysis was performed with a 1000 excess of homologous unlabeled MIN1 probe (lane 8), mutant MIN1 (lane 9), or an irrelevant binding site
(NF-B, lane 10). D, chromatin immunoprecipitations were performed from cells lysates cross-linked in the absence (Tet) or presence (Tet) of
WT1A and immunoprecipitated with WT1 antibody (lanes 1 and 2) or no antibody control (lanes 3 and 4). 1% of total input chromatin demonstrates
the presence of spry1 in both sets of lysates (lanes 5 and 6). Western blot for WT1 in bottom panel shows presence of WT1 in lysates and
immunoprecipitates. E, internal mutations were introduced into the SPRY137 promoter and tested for transactivation by WT1A.
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FIG. 4. Expression of spry1 in adult mouse tissues and in the murine embryo. A, spry1 is detected by Northern blot in several adult mouse
tissues, including the kidney. The filter was re-probed with actin to verify RNA integrity. B, ISH with mouse whole embryo sagittal sections using
a 35S-labeled spry1 antisense riboprobe (a, b, e, and f) or a wt1 antisense riboprobe (c, d, g, and h). spry1 expression is detected in the urogenital
sinus and the kidney at E11 and E15 as well as several other developing organs/tissues. wt1 expression is mostly restricted to the maturing
urogenital tract. am, anterior wall of midbrain; dm, dermomyotome; k, kidney; lm, limb muscle; o, ovary; nc, nasal cavity; op, olfactory pit; pc,
peritoneal cavity; pe, pharingeal epithelium; pm, posterior wall of midbrain; s, stomach; sm, submandibular gland; t, roof of telencephalon; tb, tail
bud; ur, urogenital ridge; us, urogenital sinus; v, vibrissae primordium.
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activation (28). This explanation is consistent with the ability
of WT1C to transactivate in the absence of DNA binding.
Expression of spry1 during Kidney Development—To deter-
mine the relationship between spry1 and wt1, the expression
pattern of spry1 was examined. In adult mouse tissues, spry1
transcripts were detected by Northern blot in heart, lung, and
most importantly, kidney (Fig. 4A). Next, we compared the
expression of wt1 and spry1 during embryonic development.
ISH of whole-embryo sections detected spry1 transcripts in
several developing organs, including the urogenital sinus, the
tail bud, and parts of the midbrain (Fig. 4B, a–b). Robust
labeling of the developing kidney was observed at E15 (Fig. 4B,
e–f). wt1 exhibited highly tissue-specific expression mostly re-
stricted to the maturing urogenital tract (Fig. 4B, c–d and g–h
and Ref. 41 and 42). Prominent wt1 expression at E11 preceded
the high level spry1 expression at E15, consistent with the
notion that WT1 is an upstream regulator of spry1.
To further correlate Spry1 and WT1 expression, murine kid-
ney rudiments from E11.5 embryos were cultured for 4 days
and analyzed by immunofluorescence. Spry1 was detected in
both the condensing mesenchyme and the ureteric tree (Fig.
5a). Moreover, double-labeling experiments using a monoclonal
anti-WT1 antibody demonstrated concordant expression of
WT1 and Spry1 proteins in the condensing metanephric mes-
enchyme (Fig. 5, b and c). Because WT1 is a nuclear protein and
Spry 1 is a cytoplasmic protein (19), the staining did not exactly
overlay. Nevertheless, these data suggest that spry1 is involved
in the development of the embryonic kidney and are consistent
with the notion that WT1 can control spry1 expression.
To map the expression of spry1 during kidney development,
explants from E11.5 embryos were cultured for 1–4 days and
subjected to ISH. spry1 exhibited a dynamic pattern during
renal development (Fig. 6. A–E). As the ureteric bud invaded
the metanephric blastema, strong spry1 expression was ob-
served in the metanephric mesenchyme condensing around the
tips of the ureteric buds (Fig. 6A, condensing mesenchyme (cm)
and arrow). The ureteric tree showed weaker expression of
spry1 mRNA (Fig. 6B, arrow). As the explant matured, spry1
was also expressed in the comma- and S-shaped bodies (Fig. 6C
and Fig. 6E, comma bodies (cb)) as well as in the ureteric tree
(Fig. 6, C and D, arrows). wt1, as reported (41, 42), was ex-
pressed in the differentiating blastema but not in the ureteric
tree (Fig. 6F). Therefore, wt1 and spry1 expression was coinci-
dent in both the uninduced and the condensing mesenchyme.
ISH performed on paraffin sections of embryonic kidneys gave
similar results (data not shown).
Murine spry1 belongs to a family of genes often co-expressed
during embryogenesis (13, 14, 26, 43). As a control for the
specificity of spry1 as a WT1 target gene in the kidney, spry2
expression was also examined (Fig. 6, G and H). spry2 was first
expressed in the ureteric bud as it invaded the metanephric
mesenchyme. It was not restricted to the ureteric epithelium
but extended into the adjacent mesenchyme (Fig. 6G, aster-
isks). In more mature explants, spry2 decreased in the ureteric
epithelium and was expressed in renal stromal cells surround-
ing the mesenchyme undergoing epithelial transition (Fig.
6H, ). In contrast to spry1, spry2 was neither expressed in the
condensing metanephric blastema nor in the comma- and S-
shaped bodies. Thus, expression of spry1 suggests a specific
role for this particular gene during metanephric development.
Disruption of Spry1 Expression in Embryonic Kidney Ex-
plants—To gain insight into the possible role of spry1 during
kidney development, we used antisense morpholinos, reported
to be more specific than traditional oligonucleotides (44), to
examine the consequences of disruption of spry1 expression in
the developing metanephric kidney. Paired murine kidney ru-
diments were isolated from E12 embryos and grown in culture
for 3 days in the absence or presence of morpholinos before
fixation and staining. Explants grown in the presence of spry1
antisense morpholinos were normal in size but exhibited a 50%
reduction in the number of developing and mature glomeruli
(visualized by peanut lectin staining of visceral podocytes (45);
Fig. 7, A, a–b, and B). This effect was specific, as explants
treated with control morpholinos (invert of the antisense or
random) developed normally. The number of ureteric branches
and tips (visualized by Dolichos bifloris lectin staining (45))
that formed in the kidney explants treated with spry1 morpho-
linos (and exhibiting less glomeruli) was not significantly dif-
ferent from control explants (data not shown). However, histo-
chemical sections revealed that ureteric trees from antisense-
FIG. 5. Co-expression of Spry1 and WT1 in the developing kidney. Four-day mouse kidney explants were simultaneously incubated with
a polyclonal rabbit serum recognizing Spry1 (a) and a monoclonal mouse antibody to WT1 (b). Spry1 was visualized with the Cy3-conjugated
antibodies against rabbit IgG, and WT1 was detected using Biodipy-conjugated antibodies against mouse IgG. Image c represents the merged
signals of the preceding two panels (ab). Spry1 protein is detected in both the condensing mesenchyme and the ureteric tree, whereas WT1 is only
present in the differentiating mesenchyme. Because WT1 is a nuclear protein and Spry1 a cytoplasmic protein, the dual signal does not generally
appear yellow.
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FIG. 6. Expression of spry1 and spry2 in murine kidney explants. Metanephric kidney rudiments were isolated from E11.5 embryos and
cultured for 1–4 days before whole-mount ISH with antisense riboprobes. A, 1-day explant showing weak spry1 expression in the ureteric canal
and intense expression in the condensing mesenchyme (cm) immediately surrounding the ends of the tips of the ureteric tree. The arrow points
to a branch point near the tip of the invading ureteric bud. B, 2-day explant showing spry1 expression in the condensing mesenchyme, the
comma-shaped bodies, and the ureteric tree (arrow). C, 3–4-day explant with spry1 expression still highest in the condensing mesenchyme. D,
magnification of the circled area in C showing weak spry1 expression in the ureteric tree (arrows). E, magnification of the squared area in C
showing spry1 expression in the comma (cb)- and S-shaped bodies as the MET occurs. F, 3–4-day explant showing wt1 expression in the condensing
mesenchyme, the comma (cb)- and S-shaped bodies. G, 1-day explant showing spry2 expression along the ureteric tree (arrow) as it invaded the
metanephric mesenchyme. spry2 expression extended in the adjacent mesenchyme (*). H, 3–4-day explant with weaker expression of spry2 in the
ureteric tree (arrows) and in between the mesenchyme that had undergone MET (; no spry2 expression was detected in the comma (cb)- or
S-shaped bodies.
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treated kidneys tended to be less elongated between branch
points and had wider, cystic, tubular lumens (Fig. 7A, c–d).
The explants were further characterized using different
markers of renal development. Pax2, a marker of early meta-
nephric development (46), was detected in the induced mesen-
chyme condensing around the ureteric bud of control explants
(Fig. 7C, a). In contrast, expression of Pax2 was strikingly
reduced in the antisense-treated explants (Fig. 7C, d), indicat-
ing a lack of condensation. Additional immunofluorescence
with antibodies against markers of the mature glomerulus,
such as synaptopodin (47) and WT1 (48), confirmed that the
glomeruli formed in the antisense-treated explants were mor-
phologically normal (Fig. 7C, b, e and c, f). Thus, the reduced
number of glomeruli observed in the antisense-treated explants
was caused by a defect in the earliest phase of epithelialization.
Given that spry1 morpholinos reduced the number of nascent
glomeruli and that these structures normally express Spry1
during kidney development, we checked the efficiency of the
morpholinos in cultured renal cells to avoid an inherent bias of
using treated kidneys. IMCD-3 cells (29) treated with spry1
morpholinos expressed less Spry1 compared with cells treated
with controls (Fig. 7D). Taken together, these data suggest that
appropriate Spry1 expression is important for the development
of both the metanephric blastema and the ureteric tree.
DISCUSSION
In the present study we have used RDA to identify spry1 as
a target gene of WT1, a transcription factor involved in renal
development and tumorigenesis. spry1 belongs to a newly iden-
tified family of receptor tyrosine kinase modulators, and our
study is the first one to identify one of their transcriptional
regulators. Endogenous spry1 expression was activated upon
constitutive or acute expression of WT1 in NIH3T3 fibroblasts.
Wild-type, but not transactivation-deficient forms of WT1, in-
duced spry1 expression in Saos-2 cells. WT1 directly bound to
the spry1 promoter both in vitro and in vivo and transactivated
FIG. 7. Disruption of Spry1 expression by antisense morpholinos affects nephrogenesis in embryonic kidney explants. A, paired
E12 mouse kidney explants grown for 3 days in medium with 20 M of spry1 antisense or control morpholinos. To visualize glomeruli, whole-mount
immunofluorescence with peanut agglutinin (PNA) was done (a and b). Sections were stained with hematoxylin/eosin to see ureteric tree
morphology upon treatment with morpholinos. c and d: cm, condensing mesenchyme; arrow, ureteric tree. Similar results were obtained in six
other experiments. B, the number of glomeruli formed was counted for each pair of kidneys (6 or 7 pairs for each condition, see “Materials and
Methods”), and the average  S.E. is presented. Ct morpho., control morpholino (invert of the antisense); AS morpho, spry1 antisense morpholino.
*, p  0.003, and **, p  0.001, by 2. C, whole mount confocal immunofluorescence for Pax2 (a and d, magnification 10), WT1 (b and e,
magnification 40) and synaptopodin (c and f, magnification 40) showing reduced condensation of the metanephric mesenchyme (arrowheads)
in the explants treated with spry1 morpholinos but normal glomeruli. D, Western blot showing decreased Spry1 expression in renal IMCD-3 cells
following spry1 antisense (AS) treatment. A glyceraldehyde-3-phosphate dehydrogenase antibody was used to assure equal protein loading.
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its expression in reporter assays through a GC-rich EGR1
binding site. Overlapping expression of wt1 and spry1 in con-
densing metanephric blastemal cells and developing glomeruli
suggests that spry1 represents a physiologically relevant target
gene of WT1. However, the regulation of spry1 in the kidney
may be complex as expression in the ureteric tree must occur
independent of WT1 expression, which is absent in this struc-
ture. Therefore, transcription factors present in both the ure-
teric tree and the condensing mesenchyme, such as Pax2,
might also regulate spry1 expression (49).
WT1 as a Transcriptional Activator—The identity of WT1
targets and the transcriptional function of WT1 have been
controversial (2). WT1 was previously thought to inhibit cell
proliferation by repression of growth-promoting genes. How-
ever, a survey using several cellular models failed to confirm
regulation of 16 genes proposed to be repressed by WT1 (50).
This information suggested that the initial characterization of
WT1 as a transcriptional repressor needed to be re-evaluated.
Now data from our group and others indicate that WT1 func-
tions by activating growth suppressor genes such as spry1, p21,
or E-cadherin (27, 28, 51) and inducing genes required for the
differentiation of the kidney such as podocalyxin (52). Eight of
11 genes identified in our RDA screen were activated by WT1
and using microarray analysis, Lee et al. (39) only found genes
activated by WT1. Previously, our group demonstrated that
three Wilms tumor-derived point mutations that abrogate the
growth inhibition by WT1 were competent for transcriptional
repression but defective for transcriptional activation of re-
porter genes (27). These same point mutants failed to up-
regulate the endogenous spry1 gene. Thus, the transcriptional
activation properties of WT1, once controversial, appear now to
be critical for its biological role.
Analysis of the spry1 promoter revealed eight potential WT1
binding sites; of these, only the 5EGR1 site was a complete
match to known WT1 sites, and only this site strongly bound
WT1. Consistent with prior reports, WT1 could also transacti-
vate without direct DNA binding (28). For example, the E-
cadherin promoter, like that of spry1, contains a CAAT box
immediately upstream of the EGR1 site (28). This CAAT box
supported minimal WT1 transactivation in the presence of a
mutation in the EGR1 site even though WT1 did not bind
directly to this element. In the amphiregulin promoter, the
CRE (cAMP-response element) adjacent to the WT1 binding
site was responsive to WT1 while not being directly bound by
WT1 (39). This was possibly due to protein-protein interactions
between WT1 and CBP (CREB-binding protein), a co-activator
of CRE binding factors. Finally, WT1 associated and synergized
with the steroidogenic factor 1 to activate mu¨llerian inhibiting
substance expression (53). Steroidogenic factor 1, but not WT1,
bound to the mu¨llerian inhibiting substance promoter. The
identification of additional WT1 co-factors, potentially those
that bind to the CAAT box, will help explain the full range of
WT1 activity.
Possible Roles for Spry1 during Kidney Development—Induc-
tion of the metanephric blastema by the invading ureteric bud
is a key step in kidney development. The ureteric bud grows out
from the wolffian duct and into the metanephric mesenchyme,
where it branches and induces nephron formation (54). Mesen-
chymal cells of the blastema condense around the ureteric bud,
undergo a MET, and form the nephric epithelium. This tightly
controlled process involves changes in cell survival, prolifera-
tion, and differentiation. WT1 is expressed in the induced
blastemal cells and plays a key role in this process. WT1 null
mice lack kidneys (5) and mice that do not express the KTS
isoforms of WT1 (WT1A and WT1B) demonstrate a decrease in
the nephrogenic zone and a reduction of the number of glomer-
uli (55). Moreover, the MET is disrupted in Wilms tumors with
a direct correlation between the level of WT1 expression and
the degree of epithelial differentiation (56).
As expected of a potential WT1 effector, Spry1 was shown to
inhibit proliferation of mesenchymal cells (23). Like WT1,
Spry1 is expressed in the condensing mesenchyme and may
relay some of the activity of WT1 during nephrogenesis. For
instance, treatment of kidney explants with spry1 morpholinos
led to fewer mature glomeruli and a defect in Pax2 expression,
suggesting a failure of induction of the metanephric mesen-
chyme adjacent to the ureteric bud. Strikingly, mice deficient
for the KTS isoforms of WT1 showed a similar lack of mes-
enchyme condensation (55). WT1 expression is also required for
the proper formation and maintenance of the glomerulus (55,
57). However, microscopic and immunofluorescence analysis of
those glomeruli that did form in the presence of spry1 morpho-
linos did not reveal any striking difference in morphology. This
could be due to an incomplete suppression of Spry1 expression
by the morpholinos. Alternatively, this might indicate that
Spry1 modulates the threshold of growth factor signaling that
allows epithelial differentiation and glomerulus formation but
is dispensable for the maintenance of the differentiated pheno-
type. Further analysis will be required to understand the exact
role of Spry1 in nephrogenesis, but the results presented here
suggest an important role for spry1 in the early stages of the
MET in the metanephric blastema and support its identifica-
tion as a WT1 target gene.
Spry1 also plays a role in the development of the ureteric
tree. Given that WT1 is not expressed in this structure, spry1
must be under the control of other transcription factors in this
region. Treatment of kidneys with spry1 morpholinos was as-
sociated with an altered, cystic morphology of the ureteric tree.
Because Spry proteins can inhibit proliferation or migration of
epithelial cells, disruption of Spry1 expression could result in
deregulated growth factor signaling and expansion of the ure-
teric epithelial lining. In support of this notion, epidermal
growth factor treatment of kidney explants (58) or excessive
glial-derived nerve growth factor signaling in mice3 leads to the
formation of similar abnormal cystic tubules. Lack of spry
expression enhanced branching morphogenesis of the tracheal
system in the fly (11). In contrast, we did not detect a change in
the number of ureteric tree branches in antisense-treated mu-
rine explants. This may be due to incomplete suppression of
Spry1 or partial rescue by Spry2 in the ureteric tree.
Initial studies did not reveal functional differences between
the different Spry members, so it was postulated that the Spry
proteins may play redundant roles (14). However, this does not
appear to be true in the kidney. spry2 was expressed in a
distinctly different pattern from spry1, and WT1 could not
induce the expression of spry2 or spry4 (data not shown).
Hence, the expression pattern of spry1 in the kidney and its
relationship with WT1 are specific.
In conclusion, our results suggest that spry1 is a bona fide
WT1 target gene. Spry1, by regulating receptor tyrosine kinase-
dependent Ras signaling, may contribute to several stages of
kidney development. Future studies of gene-targeted animals
and organ culture models will further clarify the role of the spry
genes during mammalian kidney development.
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